secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lineage Cell Therapeutics, Inc. (LCTX)
CIK:        0000876343
Form:       8-K
Filed at:   2025-01-27T23:59:59+00:00
Accession:  0000950170-25-009227
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.07, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lineage closes $6M second tranche of registered direct offering; total $30M received
--------------------------------------------------------------------------------

- Second tranche closed Jan 27, 2025; issued 7,894,737 common shares + warrants at $0.76/unit.
- Warrants exercisable at $0.91/share from May 21, 2025; expire on OpRegen Phase 2/3 milestone or May 2028.
- Potential additional $36M if all warrants exercised; $30M gross proceeds collected to date.
- Broadwood Partners (affiliate of board member Neal Bradsher) purchased the second tranche shares.
- Shareholders approved issuance at Jan 27 special meeting with 114.1M votes for, 6.7M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/876343/000095017025009227/0000950170-25-009227-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/876343/000095017025009227/lctx-20250127.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-009227

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer